Medtronic Voluntary Response To MIS Data Integrity Problems Averts AIP
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's voluntary actions to ensure data integrity in premarket submissions from its Micro Interventional Systems unit appears to have helped avert imposition of FDA's application integrity policy.
You may also be interested in...
MIS Execs Allegedly Defrauded FDA During Acquisition Talks With Medtronic
While Micro Interventional Systems was in discussions with Medtronic about a possible acquisition in November 1995, two executives at the Sunnyvale, California-based firm allegedly were falsifying data in various 510(k) submissions to FDA in an apparent attempt to impress Medtronic with the breadth of MIS' neurovascular product pipeline.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.